233 related articles for article (PubMed ID: 12586808)
1. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
[TBL] [Abstract][Full Text] [Related]
2. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
[TBL] [Abstract][Full Text] [Related]
4. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.
Maffezzini M; Campodonico F; Puntoni M; Martelli A; Mattioli F
Urology; 2009 Nov; 74(5):1078-83. PubMed ID: 19773039
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
Bassi P; De Marco V; Tavolini IM; Longo F; Pinto F; Zucchetti M; Crucitta E; Marini L; Dal Moro F
Urol Int; 2005; 75(4):309-13. PubMed ID: 16327296
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
[TBL] [Abstract][Full Text] [Related]
7. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
[TBL] [Abstract][Full Text] [Related]
8. Intravesical gemcitabine: a phase 1 and pharmacokinetic study.
Witjes JA; van der Heijden AG; Vriesema JL; Peters GJ; Laan A; Schalken JA
Eur Urol; 2004 Feb; 45(2):182-6. PubMed ID: 14734004
[TBL] [Abstract][Full Text] [Related]
9. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
De Berardinis E; Antonini G; Peters GJ; Loves WJ; Van der Born K; Codacci-Pisanelli G; Di Silverio F
BJU Int; 2004 Mar; 93(4):491-4. PubMed ID: 15008715
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer.
Campodonico F; Mattioli F; Manfredi V; Capponi G; Pasquini P; Martelli A; Maffezzini M
Anticancer Res; 2007; 27(2):1179-83. PubMed ID: 17465260
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
[TBL] [Abstract][Full Text] [Related]
12. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
Bartoletti R; Cai T; Gacci M; Giubilei G; Viggiani F; Santelli G; Repetti F; Nerozzi S; Ghezzi P; Sisani M;
Urology; 2005 Oct; 66(4):726-31. PubMed ID: 16230125
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
15. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Maffezzini M; Campodonico F; Canepa G; Capponi G; Fontana V
Eur Urol; 2007 Apr; 51(4):956-61. PubMed ID: 17027141
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
Dalbagni G; Russo P; Bochner B; Ben-Porat L; Sheinfeld J; Sogani P; Donat MS; Herr HW; Bajorin D
J Clin Oncol; 2006 Jun; 24(18):2729-34. PubMed ID: 16782913
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Gårdmark T; Carringer M; Beckman E; Malmström PU;
Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
[TBL] [Abstract][Full Text] [Related]
19. Intravesical gemcitabine: an update of clinical results.
Hendricksen K; Witjes JA
Curr Opin Urol; 2006 Sep; 16(5):361-6. PubMed ID: 16905983
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
Witjes JA; Vriesema JL; van der Heijden AG; Peters GJ; Schalken JA
Eur Urol; 2003 Nov; 44(5):615-9. PubMed ID: 14572765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]